With FDA Approval, Gefitinib Returns to U.S. Market for Some Patients with Lung Cancer



The FDA last month approved gefitinib (Iressa) for the treatment of some patients with lung cancer, marking the drug’s return to the U.S. market after an earlier withdrawal.



Source link

Comments are closed.